×

            

           PROGRAM

 

 

Monday June 8

8.30 Opening remarks

8.35 BTK strategies and best options - session 1

Moderators R. Ferraresi, A. Sauguet, E. Ducasse  
State of the art of BTK-CLI treatment
08.35 Arterial status, angiosome, arterial calcifications, is it possible to plan treatment
at BTK level?
M. Gargiulo
08.43 Big vessel versus small vessel disease: what is the true cause of critical limb ischemia? R. Ferraresi
08.51 BTK long lesions: devices and optimal treatment R. Ferraresi
08.59 Insight about ultrasound in planing, access and control of BTK angioplasty E. Puras Mallagray
09.07 BTK bifurcations: best treatment F. Airoldi
09.20 Drug eluting stent in BTK disease, K. Deloose
09.28 Bare metal stent in BTK disease E. Ducasse
09.36 Drug eluting balloon in BTK disease K. Deloose
09.44 Distal bypass in BTK disease P. Schneider
Tips & tricks & complications
10.30 Challenging BTK case E. Ducasse
10.40 When coronary devices could help? A. Sauguet
10.50 Below-the-ankle angioplasty and stenting for CLI J. Brunet
11.00 Extreme distal revascularization with conventional and alternative techniques M. Di Primio

11.20 Thoracic pathology - session 2

Moderators S. Ronchey, F. Veith  
How I deal with the aortic arch: from planning to follow-up
11.20 My experience in ascending aorta TEVAR I. Loftus
11.28 Open surgery conventional: discrepancy in results (lights and shadow) D. Pacini
11.36 Ascending aorta: is the endovascular approach realistic? T. Kölbel
11.44 Off the shelf solution: selection based on planning N. Mangialardi
11.52 My planing for arch Chimney J. Brunkwall
12.00 Endoleak after arch Chimney R. Kolvenbach
12.08 Hybrid repair: technique for total debranching P. Bergeron, A. Petrosyan
12.16 Stroke rate and mortality in arch procedure M. Lachat
12.24 Endovascular arch repair following ascending aorta open surgery T. Kölbel
12.32 Complications of supraaortic debranching S. Ronchey
12.40 Demonstration (crazy arch case) T. Larzon

14.00 Thoracic pathology - session 3

Moderators J. Busquet, F. Veith, M. Lachat, N. Mangialardi  
Dissection
14.00 We do treat all - and why, N. Cheshire
14.08 I do treat when appropriate, J. Steuer
14.16 The false channel occlusion technique T. Kölbel
14.24 TEVAR for chronic dissection I. Loftus
14.32 News from imaging will change our attitude L. Maene
Descending aorta
14.50 TEVAR European guidelines V. Riambau
14.58 How I fix endoleak in TEVAR P. Kasprzak
15.06 Clampless sutured anastomosis technique Z. Rancic
15.14 Long-term results for TEVAR after BAI R. Vallabhaneni
15.22 Access vessels challenges and best access route F. Setacci
     

15.45 : Highly complex lesions in femo/pop. What do I learn from my daily practice? - session 4

15.45 Clinical case review J. Brunet
15.57 Clinical case review M. Amor
     

16.45 Femoropopliteal disease - Part 1 - session 5

Moderators Y. Gouëffic, K. Deloose, P. Schneider, C. Setacci  
Strategy
16.45 Anti-platelet therapy: who needs it and what to prescribe K. Deloose
16.53 Popliteal artery aneurysm - What is the best mode of treatment? T. Schmitz Rixen
17.01 Radial access for femoropopliteal lesions: tips and tricks R. Coscas
17.09 Closure devices: treatment of complications J. Van den berg
TASC A/B femoropopliteal lesions
17.20 Is connected stent the good option for TASC A/B SFA lesions? E. Ducasse
  Debate. TASC A/B femoropopliteal lesions treatment  
17.35 Stent should be the first line treatment J-P. de Vries
17.43 Two-year results of a low-dose drug-coated balloon for revascularization of the
femoropopliteal artery (ILLUMENATE FIH Trial)
Y. Gouëffic
17.51 DES should be the first line treatment J. Van Den Berg
18.05 Are current stents ready for the « surgical landing-zones »? L. Maene
18.13 Lecture from China: Selective stent placement versus balloon angioplasty for
renovascular hypertension caused by Takayasu Arteritis: two-year results
X. Jiang

 

Tuesday June 9

08.15 Carotid Occlusive Disease - Are we ready for the next breakthrough? - session 6

Moderators M. Amor, P. Schneider, K. Snyder, L. Inglese  
08.15 State-of-the-art: promising next steps K. Mathias
08.30 What the data is telling us: the first 30 days need to be safer after any carotid repair,
but how?
C. Setacci
08.38 New stent designs: will they improve results? P. Schneider
08.46 New access technologies N. Cheshire
Controversy
08.54 Best medical therapy has improved: but how much, and will BMT be good
enough to replace repair?
I. Van Herzeele
08.59 Carotid endarterectomy remains the treatment of choice. The data prove it
and stents cannot compete
A. Mansilha
09.09 What is the optimal approach to asymptomatic carotid stenosis? Intervention or not?
We cannot all be correct!
A. Halliday
09.17 Challenging case: the worst complication of the year. Can you help me problem
solve?
M. Amor
09.25 Selection of stent and protection technique: which stent for which lesion M. Amor
09.33 Emergency management system: how to handle evolving stroke K. Mathias
09.41 Mechanical thrombectomy for acute stroke K. Snyder
 
10.30 Results from the ROADSTER Trial and EU Experience I. Van Herzeele
10.38 CAS revival is now P. Bergeron
10.46 Get organized for in Hospital stroke (jatrogenic or not) acute rescue L. Inglese
11.00  How I see the future of CAS F. Veith

11.15 Femoropopliteal disease - Part 2 - session 7

Moderators Y. Gouëffic, K. Deloose, P. Schneider, C. Setacci  
TASC C/D femoropopliteal lesions
11.15 Heparin bounded graft could challenge endovascular repair for TASC C-D lesions? R. Pulli
11.23 Intra versus subintimal routes to treat femoropopliteal CTO lesions: techniques and results F. Thaveau
11.31 Endovascular treatment of occluded popliteal artery aneurysm P. Veroux
Managing complications
11.45 How should we manage acute in-stent thrombosis during femoropopliteal recanalisation? Y. Gouëffic
11.53 Recurring in-stent restenosis: what is the best management?

E. Ducasse

12.01 Acute popliteal endograft occlusion: frequency and management E. Puras Mallagray
     

12.15 Next generation drug eluting technologies - session 8

12.15 Clinical results Majestic trial K. Keirse
12.35 Experience of drug eluting technologies M. Sibé
     

14.00 The A-Z of A-I disease - session 9

Moderators R. McWilliams, I. Van Herzeele  
Access
14.00 How I do PEVAR? – Video Z. Rancic
Imaging
14.08 Overlay and dose reduction during aortic procedures J. Constantinou
AAA    
14.16 Will EVAS replace EVAR? I. Loftus
14.24 EVAS and EVAR: What are the differences in case selection, deployment and surveillance? F. Torella
14.32 Single sided access for EVAR: the future M. Lachat
14.40 Review of the literature on type II endoleaks R. McWilliams
14.48 Late endoleak management – case discussions – MCQ’s J. Van Den Berg
14.56 State of the art – How I do FEVAR? P. Kasprzak
15.04 Troubleshooting after FEVAR R. Vallabhaneni
15.12 Iliac branched devices versus Iliac branched endoprothesis – differences in selection and usage F. Verzini
15.20 The lessons I have learned from RCT on RAAA management F. Veith
15.28 New evidences for hypogastric artery preservation during EVAR E. Jean-Baptiste
15.36 Tips and tricks for the CERAB technique K. Deloose
15.44 Is the endovascular world ready for 3D-printing and... vice versa? L. Maene

 


MEET 2015 - Session 4

Highly complex lesions in femo/pop. What do I learn from my daily practice?

MEET 2015 - Session 6

Carotid Occlusive Disease - Are we ready for the next breakthrough?

MEET 2015 - Session 8

Next generation drug eluting technologies

Scroll Up